{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:56:20Z","timestamp":1794264980507,"version":"4.9.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01EY023853"],"award-info":[{"award-number":["R01EY023853"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.addr.2023.115121","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T22:02:47Z","timestamp":1698444167000},"page":"115121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Injectable systems for long-lasting insulin therapy"],"prefix":"10.1016","volume":"203","author":[{"given":"Kumar Kulldeep","family":"Niloy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-0409","authenticated-orcid":false,"given":"Tao L.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.115121_b0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","article-title":"The burden and risks of emerging complications of diabetes mellitus","volume":"18","author":"Tomic","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2023.115121_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.addr.2023.115121_b0015","unstructured":"Centers for Disease Control and Prevention, National Diabetes Statistics Report, 2020, Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services, 2020."},{"key":"10.1016\/j.addr.2023.115121_b0020","first-page":"dc171962","article-title":"Global economic burden of diabetes in adults: projections from 2015 to 2030","author":"Bommer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","article-title":"Standards of medical care in diabetes-2015 abridged for primary care providers","volume":"33","author":"American Diabetes","year":"2015","journal-title":"Clin. Diabetes: Publ. Am. Diabetes Assoc."},{"key":"10.1016\/j.addr.2023.115121_b0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3343\/alm.2013.33.6.393","article-title":"HbA1c: a review of analytical and clinical aspects","volume":"33","author":"Weykamp","year":"2013","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.addr.2023.115121_b0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2213-8587(16)30010-9","article-title":"The changing face of diabetes complications","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2023.115121_b0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.addr.2017.01.006","article-title":"Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery","volume":"112","author":"Pechenov","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0045","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2337\/dc14-2898","article-title":"Glycemic variability and diabetes complications: does it matter? Of course it does!","volume":"38","author":"Hirsch","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0050","doi-asserted-by":"crossref","unstructured":"American Diabetes Association, 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018, Diabetes Care 41 (2018) S73\u2013S85.","DOI":"10.2337\/dc18-S008"},{"key":"10.1016\/j.addr.2023.115121_b0055","first-page":"17","article-title":"Efficacy of oral versus insulin therapy for newly diagnosed diabetes in low-income settings","volume":"1","author":"Vaughan","year":"2017","journal-title":"Arch. Gen. Int. Med."},{"key":"10.1016\/j.addr.2023.115121_b0060","unstructured":"M. Weiss, D.F. Steiner, L.H. Philipson, Insulin biosynthesis, secretion, structure, and structure-activity relationships, 2014."},{"key":"10.1016\/j.addr.2023.115121_b0065","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/bi4016567","article-title":"Thermodynamics of formation of the insulin hexamer: metal-stabilized proton-coupled assembly of quaternary structure","volume":"53","author":"Carpenter","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2023.115121_b0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/dia.2006.0035","article-title":"Insulin glulisine complementing basal insulins: a review of structure and activity","volume":"9","author":"Becker","year":"2007","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2023.115121_b0075","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/diacare.13.9.923","article-title":"Monomeric insulins and their experimental and clinical implications","volume":"13","author":"Brange","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/157339913804143225","article-title":"Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes","volume":"9","author":"Fu","year":"2013","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.addr.2023.115121_b0085","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.2337\/diabetes.51.2007.S37","article-title":"\u03b2-Cell mitochondria and insulin secretion: messenger role of nucleotides and metabolites","volume":"51","author":"Wollheim","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0090","series-title":"Advances in Molecular and Cell Biology","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1569-2558(08)60092-2","article-title":"Mechanism of insulin exocytosis","author":"Regazzi","year":"1999"},{"key":"10.1016\/j.addr.2023.115121_b0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1432-1327.1999.00043.x","article-title":"Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion","volume":"259","author":"Lang","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.addr.2023.115121_b0100","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0969-2126(01)00195-2","article-title":"Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin","volume":"3","author":"Ciszak","year":"1995","journal-title":"Structure"},{"key":"10.1016\/j.addr.2023.115121_b0105","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s11095-017-2233-0","article-title":"Rapid-acting and human insulins: hexamer dissociation kinetics upon dilution of the pharmaceutical formulation","volume":"34","author":"Gast","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0110","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8227(11)70014-6","article-title":"Insulin effects in muscle and adipose tissue","volume":"93","author":"Dimitriadis","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.addr.2023.115121_b0115","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dom.12501","article-title":"Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?","volume":"17","author":"Home","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2023.115121_b0120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.colsurfb.2017.02.017","article-title":"Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes","volume":"153","author":"P.V.","year":"2017","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.addr.2023.115121_b0125","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/IJN.S283416","article-title":"Advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treatment","volume":"16","author":"Li","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2023.115121_b0130","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41574-021-00542-w","article-title":"One hundred years of insulin therapy","volume":"17","author":"Mathieu","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2023.115121_b0135","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/clinchem\/48.12.2270","article-title":"Insulin: discovery and controversy","volume":"48","author":"Rosenfeld","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.addr.2023.115121_b0140","article-title":"History of insulin","volume":"2","author":"Quianzon","year":"2012","journal-title":"J. Commun. Hospital Int. Med. Perspect."},{"key":"10.1016\/j.addr.2023.115121_b0145","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1110\/ps.440101","article-title":"The effect of net charge on the solubility, activity, and stability of ribonuclease Sa","volume":"10","author":"Shaw","year":"2001","journal-title":"Protein Sci.: Publ. Protein Soc."},{"key":"10.1016\/j.addr.2023.115121_b0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ddr.20232","article-title":"Insulin: moments in history","volume":"69","author":"Rendell","year":"2008","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.addr.2023.115121_b0155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2337\/diacare.23.5.644","article-title":"Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo","volume":"23","author":"Heinemann","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2015.12.002","article-title":"Controlled release of biologics for the treatment of type 2 diabetes","volume":"240","author":"Gilroy","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/bmj.287.6391.531","article-title":"Allergy to purified bovine, porcine, and human insulins","volume":"287","author":"Wiles","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed)"},{"key":"10.1016\/j.addr.2023.115121_b0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02991108","article-title":"Insulin allergy","volume":"4","author":"Grammer","year":"1986","journal-title":"Clin. Rev. Allergy"},{"key":"10.1016\/j.addr.2023.115121_b0175","first-page":"185","article-title":"The immunogenicity of insulin preparations","volume":"205","author":"Chance","year":"1976","journal-title":"Acta Endocrinol. Suppl. (copenh)"},{"issue":"Suppl 3","key":"10.1016\/j.addr.2023.115121_b0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.16.3.155","article-title":"Immunogenicity and allergenic potential of animal and human insulins","volume":"16","author":"Schernthaner","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diabres.2015.04.002","article-title":"Clinical use of insulin degludec","volume":"109","author":"Vora","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.addr.2023.115121_b0190","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","article-title":"Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use","volume":"49","author":"Kurtzhals","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/bies.201400190","article-title":"Insulin\/receptor binding: the last piece of the puzzle?","volume":"37","author":"De Meyts","year":"2015","journal-title":"Bioessays"},{"key":"10.1016\/j.addr.2023.115121_b0200","doi-asserted-by":"crossref","first-page":"8397","DOI":"10.1021\/bi0105983","article-title":"Probing the mechanism of insulin fibril formation with insulin mutants","volume":"40","author":"Nielsen","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.addr.2023.115121_b0205","doi-asserted-by":"crossref","unstructured":"M.I. Ivanova, S.A. Sievers, M.R. Sawaya, J.S. Wall, D. Eisenberg, Molecular basis for insulin fibril assembly, Proc. Natl. Acad. Sci. 106 (2009) 18990\u201318995.","DOI":"10.1073\/pnas.0910080106"},{"key":"10.1016\/j.addr.2023.115121_b0210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1208\/s12248-016-0028-6","article-title":"Insulin formulation characterization\u2014the thioflavin T assays","volume":"19","author":"Schlein","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2023.115121_b0215","doi-asserted-by":"crossref","first-page":"10806","DOI":"10.1074\/jbc.M109.067850","article-title":"An achilles' heel in an amyloidogenic protein and its repair: insulin fibrillation and therapeutic design","volume":"285","author":"Yang","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2023.115121_b0220","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/jps.24039","article-title":"Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature","volume":"103","author":"Teska","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0225","unstructured":"A. Gualandi-Signorini, G. Giorgi, Insulin formulations-a review."},{"key":"10.1016\/j.addr.2023.115121_b0230","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2008.00874.x","article-title":"Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects*","volume":"10","author":"Becker","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2023.115121_b0235","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1093\/nar\/gkp696","article-title":"Predictable suppression of gene expression by 5\u2032-UTR-based RNA quadruplexes","volume":"37","author":"Halder","year":"2009","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.addr.2023.115121_b0240","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2337\/diab.43.3.396","article-title":"[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin","volume":"43","author":"Howey","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0245","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/dme.13692","article-title":"Lessons for modern insulin development","volume":"35","author":"Herring","year":"2018","journal-title":"Diabet. Med."},{"key":"10.1016\/j.addr.2023.115121_b0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s002280050618","article-title":"Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers","volume":"55","author":"Home","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.115121_b0255","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.2337\/diacare.25.11.2053","article-title":"A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes","volume":"25","author":"Plank","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0260","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40262-017-0514-8","article-title":"A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes","volume":"56","author":"Heise","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2023.115121_b0265","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrendo.2017.39","article-title":"Insulin analogues in type 1 diabetes mellitus: getting better all the time","volume":"13","author":"Mathieu","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2023.115121_b0270","doi-asserted-by":"crossref","unstructured":"S. Gupta, T. Chattopadhyay, M. Pal Singh, A. Surolia, Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus, Proc. Natl. Acad. Sci. 107 (2010) 13246\u201313251.","DOI":"10.1073\/pnas.1005704107"},{"key":"10.1016\/j.addr.2023.115121_b0275","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/dmrr.2469","article-title":"Basal insulin analogues in the management of diabetes mellitus: what progress have we made?","volume":"30","author":"Owens","year":"2014","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114322","article-title":"Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery","volume":"186","author":"Klepach","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0285","doi-asserted-by":"crossref","first-page":"e2100172","DOI":"10.1002\/bies.202100172","article-title":"Fatty acids may influence insulin dynamics through modulation of albumin-Zn(2+) interactions","volume":"43","author":"Arya","year":"2021","journal-title":"Bioessays"},{"key":"10.1016\/j.addr.2023.115121_b0290","doi-asserted-by":"crossref","unstructured":"J. Rosenstock, S.L. Schwartz, C.M. Clark, G.D. Park, D.W. Donley, M.B. Edwards, Basal Insulin Therapy in Type 2 Diabetes, 28-week comparison of insulin glargine (HOE 901) and NPH insulin 24 (2001) 631\u2013636.","DOI":"10.2337\/diacare.24.4.631"},{"key":"10.1016\/j.addr.2023.115121_b0295","doi-asserted-by":"crossref","unstructured":"J. Rosenstock, G. Dailey, M. Massi-Benedetti, A. Fritsche, Z. Lin, A. Salzman, Reduced Hypoglycemia Risk With Insulin Glargine, A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes 28 (2005) 950\u2013955.","DOI":"10.2337\/diacare.28.4.950"},{"key":"10.1016\/j.addr.2023.115121_b0300","first-page":"213","article-title":"Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs","volume":"2","author":"Poon","year":"2010","journal-title":"Drug, Healthcare Patient Safety"},{"key":"10.1016\/j.addr.2023.115121_b0305","doi-asserted-by":"crossref","unstructured":"R.K. Pollom, T. Costigan, L.B. Lacaya, L.L. Ilag, P.A. Hollander, Similar Efficacy and Safety of Basaglar((R)) and Lantus((R)) in Patients with Type 2 Diabetes in Age Groups (< 65 Years, >\/= 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study, Diabetes therapy : research, treatment and education of diabetes and related disorders, 9 (2018) 827-837.","DOI":"10.1007\/s13300-018-0405-5"},{"key":"10.1016\/j.addr.2023.115121_b0310","doi-asserted-by":"crossref","unstructured":"P. Home, P. Bartley, D. Russell-Jones, H. Hanaire-Broutin, J.-E. Heeg, P. Abrams, M. Landin-Olsson, B. Hylleberg, H. Lang, E. Draeger, Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes, A randomized clinical trial 27 (2004) 1081\u20131087.","DOI":"10.2337\/diacare.27.5.1081"},{"key":"10.1016\/j.addr.2023.115121_b0315","doi-asserted-by":"crossref","unstructured":"S.G. Swinnen, A.C. Simon, F. Holleman, J.B. Hoekstra, J.H. Devries, Insulin detemir versus insulin glargine for type 2 diabetes mellitus, The Cochrane database of systematic reviews (2011) Cd006383.","DOI":"10.1002\/14651858.CD006383.pub2"},{"key":"10.1016\/j.addr.2023.115121_b0320","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/dmrr.989","article-title":"Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes","volume":"25","author":"Raskin","year":"2009","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0325","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diabetes.53.6.1614","article-title":"Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes","volume":"53","author":"Heise","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0330","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diacare.27.2.632","article-title":"Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal\/bolus therapy","volume":"27","author":"Albright","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0335","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.2337\/dcS15-3011","article-title":"New long-acting basal insulins: does benefit outweigh cost?","volume":"39","author":"Standl","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0340","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.amjmed.2018.01.049","article-title":"New injectable agents for the treatment of type 2 diabetes part 1 \u2013 injectable insulins","volume":"131","author":"George","year":"2018","journal-title":"Am. J. Med."},{"key":"10.1016\/j.addr.2023.115121_b0345","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/dc16-0684","article-title":"Comparison of insulin glargine 300 Units\/mL and 100 Units\/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections","volume":"40","author":"Bergenstal","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0350","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 Units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL-1","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0355","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009421","article-title":"Safety and efficacy of insulin glargine 300 u\/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"6","author":"Freemantle","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.addr.2023.115121_b0360","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","article-title":"A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U\/mL formulations of ultra-long-acting insulin degludec","volume":"33","author":"Korsatko","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.addr.2023.115121_b0365","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","article-title":"A review of the pharmacological properties of insulin degludec and their clinical relevance","volume":"53","author":"Haahr","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2023.115121_b0370","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","article-title":"Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin","volume":"29","author":"Jonassen","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0375","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","article-title":"Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2023.115121_b0380","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2023.115121_b0385","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jdi.12502","article-title":"Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: a randomized, 26-week, treat-to-target trial","volume":"7","author":"Kadowaki","year":"2016","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.addr.2023.115121_b0390","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jc.2012-3249","article-title":"Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension","volume":"98","author":"Mathieu","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2023.115121_b0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12020-016-0917-6","article-title":"Premixed insulin regimens in type 2 diabetes: pros","volume":"55","author":"Maiorino","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.addr.2023.115121_b0400","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-200666010-00003","article-title":"Premixed insulin analogues for the treatment of diabetes mellitus","volume":"66","author":"Garber","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2023.115121_b0405","unstructured":"N. All\u00e9, Ryzodeg\u00ae provides successful glycaemic control with fewer injections than a basal-bolus regimen."},{"key":"10.1016\/j.addr.2023.115121_b0410","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/dom.14128","article-title":"Practical use of insulin degludec\/insulin aspart in a multinational setting: beyond the guidelines","volume":"22","author":"Mehta","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2023.115121_b0415","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.colsurfb.2017.02.017","article-title":"Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes","volume":"153","author":"P","year":"2017","journal-title":"Colloids Surf. B Biointerf."},{"key":"10.1016\/j.addr.2023.115121_b0420","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.nanolett.6b03848","article-title":"Hypoxia and H2O2 dual-sensitive vesicles for enhanced glucose-responsive insulin delivery","volume":"17","author":"Yu","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2023.115121_b0425","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jama.2017.6939","article-title":"Human insulin for type 2 diabetes: an effective, less-expensive option","volume":"318","author":"Lipska","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.addr.2023.115121_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113957","article-title":"Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: inserts, patches, wafers, and implants","volume":"177","author":"Abdelkader","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114280","article-title":"Medical devices, smart drug delivery, wearables and technology for the treatment of diabetes mellitus","volume":"185","author":"Domingo-Lopez","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0440","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12902-023-01292-8","article-title":"Comparison of simplicity, convenience, safety, and cost-effectiveness between use of insulin pen devices and disposable plastic syringes by patients with type 2 diabetes mellitus: a cross-sectional study from Bangladesh","volume":"23","author":"Kamrul-Hasan","year":"2023","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.addr.2023.115121_b0445","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4239\/wjd.v11.i8.358","article-title":"Access to insulin delivery devices and glycated haemoglobin in lower-income countries","volume":"11","author":"Klatman","year":"2020","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0450","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/193229681000400302","article-title":"Evolution of diabetes insulin delivery devices","volume":"4","author":"Selam","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2023.115121_b0455","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2337\/diacare.22.1.137","article-title":"Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes","volume":"22","author":"Lteif","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0460","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/17425247.2016.1232247","article-title":"Challenges and recent advances in the subcutaneous delivery of insulin","volume":"14","author":"Guo","year":"2017","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115121_b0465","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2337\/dc11-0182","article-title":"Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology","volume":"34","author":"Engwerda","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0470","doi-asserted-by":"crossref","first-page":"e5482","DOI":"10.1097\/MD.0000000000005482","article-title":"Comparison of jet injector and insulin pen in controlling plasma glucose and insulin concentrations in type 2 diabetic patients","volume":"96","author":"Guo","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.addr.2023.115121_b0475","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.2337\/dc13-0492","article-title":"Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes","volume":"36","author":"Engwerda","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2023.115121_b0480","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.13994","article-title":"Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes","volume":"318","author":"Karges","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.addr.2023.115121_b0485","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/dom.12642","article-title":"Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial","volume":"18","author":"Aronson","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2023.115121_b0490","first-page":"108","volume":"1","author":"Parkes","year":"1939","journal-title":"The influence of the subcutaneous implantation of tablets of solid insulin on the blood sugar level of the rabbit"},{"key":"10.1016\/j.addr.2023.115121_b0495","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/BF01928732","article-title":"Control of diabetes with polyacrylamide implants containing insulin","volume":"28","author":"Davis","year":"1972","journal-title":"Experientia"},{"key":"10.1016\/j.addr.2023.115121_b0500","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2337\/diab.29.1.37","article-title":"One month of sustained release of insulin from a polymer implant","volume":"29","author":"Creque","year":"1980","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0505","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2337\/diab.31.6.506","article-title":"Prolonged hypoglycemic effect in diabetic dogs due to subcutaneous administration of insulin in liposomes","volume":"31","author":"Stevenson","year":"1982","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0510","first-page":"205","article-title":"Insulin-albumin microbeads: an implantable, biodegradable system","volume":"10","author":"Goosen","year":"1982","journal-title":"Biomater. Med. Dev. Artif. Org."},{"key":"10.1016\/j.addr.2023.115121_b0515","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2337\/diab.32.5.478","article-title":"Slow release of insulin from a biodegradable matrix implanted in diabetic rats","volume":"32","author":"Goosen","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0520","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10731198509118850","article-title":"Microencapsulation and controlled release of insulin from polylactic acid microcapsules","volume":"13","author":"Lin","year":"1985","journal-title":"Biomater. Med. Dev. Artif. Organs"},{"key":"10.1016\/j.addr.2023.115121_b0525","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3109\/10731198809117571","article-title":"Insulin controlled-release microcapsules to prolong the hypoglycemic effect in diabetic rats","volume":"16","author":"Lin","year":"1988","journal-title":"Biomater. Artif. Cells Artif. Organs"},{"key":"10.1016\/j.addr.2023.115121_b0530","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4155\/tde.14.5","article-title":"Recent developments in protein and peptide parenteral delivery approaches","volume":"5","author":"Patel","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2023.115121_b0535","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/17425247.2015.961420","article-title":"Long-term delivery of protein therapeutics","volume":"12","author":"Vaishya","year":"2015","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2023.115121_b0540","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1745-7254.2008.00881.x","article-title":"Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration","volume":"29","author":"Zhang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2023.115121_b0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40204-014-0033-8","article-title":"Development of microspheres for biomedical applications: a review","volume":"4","author":"Hossain","year":"2014","journal-title":"Prog. Biomater."},{"key":"10.1016\/j.addr.2023.115121_b0550","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2010.05.011","article-title":"Issues in long-term protein delivery using biodegradable microparticles","volume":"146","author":"Ye","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0555","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-3659(01)00518-1","article-title":"A novel sustained-release formulation of insulin with dramatic reduction in initial rapid release","volume":"79","author":"Takenaga","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0560","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/10717540500315989","article-title":"Administration of optimum sustained-insulin release PLGA microcapsules to spontaneous diabetes-prone BB\/Wor\/\/Tky rats","volume":"13","author":"Takenaga","year":"2006","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2023.115121_b0565","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0168-3659(02)00060-3","article-title":"Insulin-loaded biodegradable PLGA microcapsules: initial burst release controlled by hydrophilic additives","volume":"81","author":"Yamaguchi","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0570","doi-asserted-by":"crossref","unstructured":"F. Kang, J. Singh, Preparation, in vitro release, in vivo absorption and biocompatibility studies of insulin-loaded microspheres in rabbits, AAPS PharmSciTech 6 (2005) E487\u2013E494.","DOI":"10.1208\/pt060361"},{"key":"10.1016\/j.addr.2023.115121_b0575","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1016\/j.biomaterials.2012.08.042","article-title":"Multi-arm histidine copolymer for controlled release of insulin from poly(lactide-co-glycolide) microsphere","volume":"33","author":"Park","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115121_b0580","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0885328208096238","article-title":"Evaluation of parenteral depot insulin formulation using PLGA and PLA microparticles","volume":"24","author":"Naha","year":"2009","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.addr.2023.115121_b0585","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/02652048.2011.621554","article-title":"Effect of PLGA hydrophilia on the drug release and the hypoglucemic activity of different insulin-loaded PLGA microspheres","volume":"28","author":"Presmanes","year":"2011","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2023.115121_b0590","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/10717544.2017.1381200","article-title":"Insulin-loaded PLGA microspheres for glucose-responsive release","volume":"24","author":"Wu","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2023.115121_b0595","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3109\/03639040902939213","article-title":"Preparation, characterization, and in vivo evaluation of insulin-loaded PLA-PEG microspheres for controlled parenteral drug delivery","volume":"35","author":"Sheshala","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0600","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s11095-012-0880-8","article-title":"Evaluation of poly (1, 6-bis-(p-carboxyphenoxy) hexane-co-sebacic acid microspheres for controlled basal insulin delivery","volume":"30","author":"Manoharan","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0605","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1002\/jps.21741","article-title":"Evaluation of polyanhydride microspheres for basal insulin delivery: effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo absorption and bioactivity in diabetic rats","volume":"98","author":"Manoharan","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0610","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1081\/DDC-120018644","article-title":"Potential applications of polymeric microsphere suspension as subcutaneous depot for insulin","volume":"29","author":"Shenoy","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0615","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2023.115121_b0620","doi-asserted-by":"crossref","unstructured":"H. Hamishehkar, J. Emami, A.R. Najafabadi, K. Gilani, M. Minaiyan, H. Mahdavi, A. Nokhodchi, The effect of formulation variables on the characteristics of insulin-loaded poly(lactic-co-glycolic acid) microspheres prepared by a single phase oil in oil solvent evaporation method, Colloids Surf. B: Biointerf. 74 (2009) 340\u2013349.","DOI":"10.1016\/j.colsurfb.2009.08.003"},{"key":"10.1016\/j.addr.2023.115121_b0625","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejps.2008.09.008","article-title":"Novel composite microparticles for protein stabilization and delivery","volume":"36","author":"Schoubben","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0630","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/02652040600687613","article-title":"PLGA microspheres with high drug loading and high encapsulation efficiency prepared by a novel solvent evaporation technique","volume":"23","author":"Bao","year":"2006","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.addr.2023.115121_b0635","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2009.05.021","article-title":"Insulin nanoparticle preparation and encapsulation into poly(lactic-co-glycolic acid) microspheres by using an anhydrous system","volume":"378","author":"Han","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0640","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijpharm.2018.09.007","article-title":"Effect of excipients on encapsulation and release of insulin from spray-dried solid lipid microparticles","volume":"550","author":"Wu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0645","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jconrel.2014.09.003","article-title":"Microencapsulation of protein drugs for drug delivery: strategy, preparation, and applications","volume":"193","author":"Ma","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0650","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijpharm.2015.10.057","article-title":"Double emulsion solvent evaporation techniques used for drug encapsulation","volume":"496","author":"Iqbal","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0655","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3390\/polym7050836","article-title":"Addition of zinc improves the physical stability of insulin in the primary emulsification step of the poly(lactide-co-glycolide) microsphere preparation process","volume":"7","author":"Manoharan","year":"2015","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2023.115121_b0660","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jps.21445","article-title":"Insulin loaded PLGA microspheres: effect of zinc salts on encapsulation, release, and stability","volume":"98","author":"Manoharan","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0665","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/mp060120z","article-title":"Role of a novel excipient poly(ethylene glycol)-b-poly(L-histidine) in retention of physical stability of insulin at aqueous\/organic interface","volume":"4","author":"Taluja","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0670","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejpb.2010.03.005","article-title":"Effect of various additives and polymers on lysozyme release from PLGA microspheres prepared by an s\/o\/w emulsion technique","volume":"75","author":"Paillard-Giteau","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115121_b0675","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2017.03.396","article-title":"Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres","volume":"255","author":"Andhariya","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0680","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.xphs.2017.10.027","article-title":"Beyond Q1\/Q2: the impact of manufacturing conditions and test methods on drug release from PLGA-based microparticle depot formulations","volume":"107","author":"Garner","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0685","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1081\/DDC-100107331","article-title":"Emulsion spray-drying for the preparation of albumin-loaded PLGA microspheres","volume":"27","author":"Giunchedi","year":"2001","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0690","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0168-3659(02)00414-5","article-title":"Feeding liquid, non-ionic surfactant and cyclodextrin affect the properties of insulin-loaded poly(lactide-co-glycolide) microspheres prepared by spray-drying","volume":"86","author":"Quaglia","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0695","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11095-018-2538-7","article-title":"Physicochemical characterization and pharmacokinetics of agomelatine-loaded PLGA microspheres for intramuscular injection","volume":"36","author":"Zhang","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0700","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2006.10.036","article-title":"Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres","volume":"334","author":"Mao","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0705","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s13346-016-0278-y","article-title":"Preparation, characterization, and in vitro release studies of insulin-loaded double-walled poly(lactide-co-glycolide) microspheres","volume":"6","author":"Ansary","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2023.115121_b0710","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/10426914.2014.984219","article-title":"Manufacture, characterization, and release profiles of insulin-loaded mesoporous PLGA microspheres","volume":"31","author":"Shi","year":"2016","journal-title":"Mater. Manuf. Process."},{"key":"10.1016\/j.addr.2023.115121_b0715","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1007\/s11095-015-1686-2","article-title":"Long-acting injectable hormonal dosage forms for contraception","volume":"32","author":"Wu","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0720","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040263","article-title":"A comprehensive map of FDA-approved pharmaceutical products","volume":"10","author":"Zhong","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.115121_b0725","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/1753-0407.12603","article-title":"American association of diabetes educators 2017","volume":"9","author":"Carracher","year":"2017","journal-title":"J. Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154924","article-title":"Basal weekly insulins: the way of the future!","volume":"126","author":"Rosenstock","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.addr.2023.115121_b0735","first-page":"A25","article-title":"The in vitro and in vivo pharmacology of AB101, a potential once-weekly basal subcutaneous insulin","volume":"64","author":"Roberts","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b0740","unstructured":"B.K. Roberts, The In Vitro and In Vivo Pharmacology of AB101, a Potential Once-Weekly Basal Subcutaneous Insulin, 2015."},{"key":"10.1016\/j.addr.2023.115121_b0745","doi-asserted-by":"crossref","unstructured":"AntraBio, AntraBio Q2 2017, 2017.","DOI":"10.1016\/j.fopow.2017.11.007"},{"key":"10.1016\/j.addr.2023.115121_b0750","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2004.03.003","article-title":"In situ forming parenteral drug delivery systems: an overview","volume":"58","author":"Packhaeuser","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115121_b0755","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0168-3659(02)00008-1","article-title":"Biodegradable injectable in situ forming drug delivery systems","volume":"80","author":"Hatefi","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0760","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.addr.2023.115121_b0765","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.drudis.2013.01.013","article-title":"Injectable implants for the sustained release of protein and peptide drugs","volume":"18","author":"Agarwal","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2023.115121_b0770","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","article-title":"In situ forming implants \u2014 an attractive formulation principle for parenteral depot formulations","volume":"161","author":"Kempe","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0775","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pharmaceutics8030028","article-title":"An accelerated release study to evaluate long-acting contraceptive levonorgestrel-containing in situ forming depot systems","volume":"8","author":"Janagam","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.115121_b0780","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/S0142-9612(00)00106-X","article-title":"Injectable biodegradable polymer composites based on poly(propylene fumarate) crosslinked with poly(ethylene glycol)-dimethacrylate","volume":"21","author":"He","year":"2000","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115121_b0785","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0168-3659(98)00125-4","article-title":"Photopolymerization of multilaminated poly(HEMA) hydrogels for controlled release","volume":"57","author":"Lu","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0790","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2012.07.035","article-title":"Chitosan-zinc-insulin complex incorporated thermosensitive polymer for controlled delivery of basal insulin in vivo","volume":"163","author":"Oak","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0795","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0378-5173(99)00119-2","article-title":"Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats","volume":"184","author":"Barichello","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0800","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.carbpol.2010.04.068","article-title":"Effects of interpenetration of thermo-sensitive gels by crosslinking of chitosan on nasal delivery of insulin: in vitro characterization and in vivo study","volume":"82","author":"Chung","year":"2010","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.addr.2023.115121_b0805","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jddst.2018.03.028","article-title":"Combination of coating and injectable hydrogel depot to improve the sustained delivery of insulin","volume":"45","author":"Yang","year":"2018","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2023.115121_b0810","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2015.12.015","article-title":"PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery","volume":"240","author":"Cho","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0815","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1023\/A:1011074915438","article-title":"Controlled release of insulin from injectable biodegradable triblock copolymer","volume":"18","author":"Kim","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0820","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1023\/B:PHAM.0000008050.99985.5c","article-title":"Controlled release of insulin from injectable biodegradable triblock copolymer depot in ZDF rats","volume":"20","author":"Choi","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0825","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1002\/jps.22685","article-title":"Basal level insulin delivery: in vitro release, stability, biocompatibility, and in vivo absorption from thermosensitive triblock copolymers","volume":"100","author":"Al-Tahami","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0830","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.biomaterials.2008.02.016","article-title":"Functionalized injectable hydrogels for controlled insulin delivery","volume":"29","author":"Huynh","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115121_b0835","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2009.03.008","article-title":"Enzymatically degradable temperature-sensitive polypeptide as a new in-situ gelling biomaterial","volume":"137","author":"Jeong","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0840","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3109\/10717544.2014.932861","article-title":"In vitro and in vivo evaluation of thermosensitive chitosan hydrogel for sustained release of insulin","volume":"23","author":"Ghasemi Tahrir","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2023.115121_b0845","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1039\/c0sm01285h","article-title":"Biodegradable oligo(amidoamine\/\u03b2-amino ester) hydrogels for controlled insulin delivery","volume":"7","author":"Nguyen","year":"2011","journal-title":"Soft Matter"},{"key":"10.1016\/j.addr.2023.115121_b0850","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2009.02.021","article-title":"Controlled release of insulin from pH\/temperature-sensitive injectable pentablock copolymer hydrogel","volume":"137","author":"Huynh","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0855","doi-asserted-by":"crossref","first-page":"1700097","DOI":"10.1002\/adbi.201700097","article-title":"Injectable in situ forming depot systems for long-acting contraception","volume":"1","author":"Janagam","year":"2017","journal-title":"Adv. Biosyst."},{"key":"10.1016\/j.addr.2023.115121_b0860","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1039\/C8BM00006A","article-title":"Injectable self-assembled peptide hydrogels for glucose-mediated insulin delivery","volume":"6","author":"Fu","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0865","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/187221107779814113","article-title":"Smart polymer based delivery systems for peptides and proteins","volume":"1","author":"Khaled","year":"2007","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.addr.2023.115121_b0870","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1016\/j.biomaterials.2009.05.052","article-title":"pH-triggered injectable hydrogels prepared from aqueous N-palmitoyl chitosan: In vitro characteristics and in vivo biocompatibility","volume":"30","author":"Chiu","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115121_b0875","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/157016311795563848","article-title":"Hydrogels based on interpenetrating network of chitosan and polyvinyl pyrrolidone for pH-sensitive delivery of repaglinide","volume":"8","author":"Vaghani","year":"2011","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.addr.2023.115121_b0880","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13233-010-0315-5","article-title":"Bioadhesive PAA-PEG-PAA triblock copolymer hydrogels for drug delivery in oral cavity","volume":"18","author":"Nguyen","year":"2010","journal-title":"Macromol. Res."},{"key":"10.1016\/j.addr.2023.115121_b0885","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12272-010-0409-9","article-title":"Galactosylated chitosan-g-PEI\/DNA complexes-loaded poly(organophosphazene) hydrogel as a hepatocyte targeting gene delivery system","volume":"33","author":"Jiang","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0890","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejpb.2010.06.012","article-title":"Enhancement of sustained and controlled protein release using polyelectrolyte complex-loaded injectable and thermosensitive hydrogel","volume":"76","author":"Park","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115121_b0895","first-page":"1","article-title":"Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant","volume":"1","author":"Ravivarapu","year":"2000","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2023.115121_b0900","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1023\/A:1018943107688","article-title":"Sustained release of human growth hormone from PLGA solution depots","volume":"16","author":"Brodbeck","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0905","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/0885328209359959","article-title":"Development and evaluation of in situ gel-forming system for sustained delivery of insulin","volume":"25","author":"Dhawan","year":"2011","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.addr.2023.115121_b0910","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1208\/s12249-011-9744-5","article-title":"Controlled release of modified insulin glargine from novel biodegradable injectable gels","volume":"13","author":"Anand","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2023.115121_b0915","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/187221107779814113","article-title":"Smart polymer based delivery systems for peptides and proteins","volume":"1","author":"Al-Tahami","year":"2007","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.addr.2023.115121_b0920","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1002\/jps.24558","article-title":"The effect of additives on the behavior of phase sensitive in situ forming implants","volume":"104","author":"Solorio","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0925","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jpba.2017.07.056","article-title":"Phase separation of in situ forming poly (lactide-co-glycolide acid) implants investigated using a hydrogel-based subcutaneous tissue surrogate and UV\u2013vis imaging","volume":"145","author":"Sun","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2023.115121_b0930","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/0250-474X.56015","article-title":"In situ forming polymeric drug delivery systems","volume":"71","author":"Madan","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0935","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jconrel.2010.08.020","article-title":"Effect of injection site on in situ implant formation and drug release in vivo","volume":"147","author":"Patel","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0940","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","article-title":"PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release","volume":"172","author":"Parent","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b0945","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/15583724.2014.927885","article-title":"Pluronic F127-based thermosensitive gels for delivery of therapeutic proteins and peptides","volume":"54","author":"Akash","year":"2014","journal-title":"Polym. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0950","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.xphs.2018.04.011","article-title":"Bioadhesive chitosan-coated cationic nanoliposomes with improved insulin encapsulation and prolonged oral hypoglycemic effect in diabetic mice","volume":"107","author":"Shalaby","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2023.115121_b0955","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpba.2017.11.065","article-title":"Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV\u2013vis imaging","volume":"150","author":"Sun","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.addr.2023.115121_b0960","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1016\/j.biomaterials.2012.09.016","article-title":"The use of pH-sensitive positively charged polymeric micelles for protein delivery","volume":"33","author":"Gao","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115121_b0965","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.addr.2017.04.001","article-title":"Nanoparticles for drug delivery to the anterior segment of the eye","volume":"122","author":"Janagam","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115121_b0970","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1007\/s11095-007-9367-4","article-title":"Alginate\/chitosan nanoparticles are effective for oral insulin delivery","volume":"24","author":"Sarmento","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b0975","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijbiomac.2014.08.040","article-title":"pH-sensitive chitosan\/alginate core-shell nanoparticles for efficient and safe oral insulin delivery","volume":"72","author":"Mukhopadhyay","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2023.115121_b0980","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.2147\/IJN.S81715","article-title":"pH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulin","volume":"10","author":"Sun","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.addr.2023.115121_b0985","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jddst.2017.10.004","article-title":"Effect of process variables on formulation, in-vitro characterisation and subcutaneous delivery of insulin PLGA nanoparticles: an optimisation study","volume":"43","author":"Abdelkader","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.addr.2023.115121_b0990","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijpharm.2015.12.063","article-title":"Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG","volume":"499","author":"Haggag","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2023.115121_b0995","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.biomaterials.2011.10.072","article-title":"A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles","volume":"33","author":"Peng","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.115121_b1000","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2015.12.036","article-title":"Injectable insulin-lysozyme-loaded nanogels with enzymatically-controlled degradation and release for basal insulin treatment: In vitro characterization and in vivo observation","volume":"224","author":"Chou","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.115121_b1005","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1021\/nn400630x","article-title":"Injectable nano-network for glucose-mediated insulin delivery","volume":"7","author":"Gu","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2023.115121_b1010","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1021\/acs.chemmater.7b01804","article-title":"Glucose-responsive nanosystem mimicking the physiological insulin secretion via an enzyme-polymer layer-by-layer coating strategy","volume":"29","author":"Xu","year":"2017","journal-title":"Chem. Mater."},{"key":"10.1016\/j.addr.2023.115121_b1015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2020.11.008","article-title":"Clinically established biodegradable long acting injectables: an industry perspective","volume":"167","author":"Nkanga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2023.115121_b1020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.tips.2022.05.001","article-title":"Nanomedicine: controlling nanoparticle clearance for translational success","volume":"43","author":"Zhu","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.addr.2023.115121_b1025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41578-018-0038-3","article-title":"Transport and interactions of nanoparticles in the kidneys","volume":"3","author":"Du","year":"2018","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.addr.2023.115121_b1030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrd4477","article-title":"Managing diabetes with nanomedicine: challenges and opportunities","volume":"14","author":"Veiseh","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.115121_b1035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0883911515569919","article-title":"Injectable microspheres for extended delivery of bioactive insulin and salicylic acid","volume":"30","author":"Yu","year":"2015","journal-title":"J. Bioact. Compat. Polym."},{"key":"10.1016\/j.addr.2023.115121_b1040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrd4477","article-title":"Managing diabetes with nanomedicine: challenges and opportunities","volume":"14","author":"Veiseh","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.115121_b1045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.actbio.2017.09.044","article-title":"An injectable particle-hydrogel hybrid system for glucose-regulatory insulin delivery","volume":"64","author":"Zhao","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2023.115121_b1050","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s10856-007-3010-0","article-title":"Controlled release of insulin from PLGA nanoparticles embedded within PVA hydrogels","volume":"18","author":"Liu","year":"2007","journal-title":"J. Mater. Sci. - Mater. Med."},{"key":"10.1016\/j.addr.2023.115121_b1055","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration: should it be used in experimental animal studies?","volume":"37","author":"Al Shoyaib","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.115121_b1060","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1016\/j.actbio.2012.09.034","article-title":"Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin","volume":"9","author":"Peng","year":"2013","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2023.115121_b1065","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.2174\/1381612821666151008124322","article-title":"Nanoembedded microparticles for stabilization and delivery of drug-loaded nanoparticles","volume":"21","author":"Bohr","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2023.115121_b1070","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejpb.2012.10.016","article-title":"Production of nanoparticles-in-microparticles by a double emulsion method: a comprehensive study","volume":"83","author":"Lee","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.115121_b1075","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jddst.2015.06.020","article-title":"Reduction of the in vivo burst release of insulin-loaded microparticles","volume":"30","author":"Sheikh Hasan","year":"2015","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.addr.2023.115121_b1080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrd.2015.36","article-title":"Pursuit of a perfect insulin","volume":"15","author":"Zaykov","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2023.115121_b1085","unstructured":"B.K. Roberts, X. Wang, M. Rosendahl, S. Mantriprigada, The Extended Duration Single Dose Pharmacokinetics (PK) and Pharmacodynamics (PD) of AB101, a Potential Once Weekly Basal Subcutaneous (SC) Insulin, in Diabetic Miniature Swine, DIABETES, AMER DIABETES ASSOC 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA, 2016, pp. A246-A247."},{"key":"10.1016\/j.addr.2023.115121_b1090","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/dom.13006","article-title":"(LAPS) Insulin115: a novel ultra-long-acting basal insulin with a unique action profile","volume":"19","author":"Wronkowitz","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2023.115121_b1095","first-page":"100","article-title":"A novel very long-acting insulin analog (HM12470) with potential for once-weekly dosing, has a favorable PK, PD and mitogenic profile","volume":"100","author":"Hwang","year":"2014","journal-title":"Insulin"},{"key":"10.1016\/j.addr.2023.115121_b1100","unstructured":"S. Hwang, J. Kim, J. Kim, I. Choi, M. Hompesch, S. Kwon, Underlying Mechanisms for Long-Acting Properties of the Novel Weekly Insulin, LAPS Insulin 115 (HM12470)."},{"key":"10.1016\/j.addr.2023.115121_b1105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2023.115121_b1110","article-title":"Therapeutic agents, compositions, and methods for glycemic control","author":"Jowett","year":"2015","journal-title":"Google Patents"},{"key":"10.1016\/j.addr.2023.115121_b1115","unstructured":"Diabetes News Journal, Type 2 diabetes study of once-weekly insulin treatment now enrolling patients, November 12 2015."},{"key":"10.1016\/j.addr.2023.115121_b1120","unstructured":"PhaseBio, PhaseBio announces initiation of phase 2a multiple ascending dose study of once-weekly basal insulin PE0139 in type 2 diabetes, 2015, November 9."},{"key":"10.1016\/j.addr.2023.115121_b1125","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1021\/acs.jmedchem.1c00257","article-title":"Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans","volume":"64","author":"Kjeldsen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.addr.2023.115121_b1130","doi-asserted-by":"crossref","DOI":"10.2337\/db20-237-OR","article-title":"237-OR: insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes","volume":"69","author":"H\u00f6velmann","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2023.115121_b1135","doi-asserted-by":"crossref","unstructured":"K.K. Cheung, P. Alexander, Sr., Novel and emerging insulin preparations for type 2 diabetes, Can. J. Diabet. 39 Suppl 5 (2015) S160\u2013S166.","DOI":"10.1016\/j.jcjd.2015.09.082"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23004362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23004362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:42:13Z","timestamp":1759210933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23004362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":227,"alternative-id":["S0169409X23004362"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.115121","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Injectable systems for long-lasting insulin therapy","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.115121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115121"}}